

The structure of ribosome-lankacidin complex reveals ribosomal sites for synergistic antibiotics

Tamar Auerbach^a, Inbal Mermershtain^a, Chen Davidovich^a, Anat Bashan^a, Matthew Belousoff^a, Itai Wekselman^a, Ella Zimmerman^a, Liqun Xiong^b, Dorota Klepacki^b, Kenji Arakawa^c, Haruyasu Kinashi^c, Alexander S. Mankin^{b,1}, and Ada Yonath^{a,1}

^aDepartment of Structural Biology, Weizmann Institute of Science, Rehovot 76100, Israel; ^bCenter for Pharmaceutical Biotechnology, University of Illinois at Chicago, IL 60607; and ^cDepartment of Molecular Biotechnology, Graduate School of Advanced Sciences of Matter, Hiroshima University, Higashi-Hiroshima 739-8530, Japan

Contributed by Ada Yonath, December 15, 2009 (sent for review September 8, 2009)

Crystallographic analysis revealed that the 17-member polyketide antibiotic lankacidin produced by *Streptomyces rochei* binds at the peptidyl transferase center of the eubacterial large ribosomal subunit. Biochemical and functional studies verified this finding and showed interference with peptide bond formation. Chemical probing indicated that the macrolide lankamycin, a second antibiotic produced by the same species, binds at a neighboring site, at the ribosome exit tunnel. These two antibiotics can bind to the ribosome simultaneously and display synergy in inhibiting bacterial growth. The binding site of lankacidin and lankamycin partially overlap with the binding site of another pair of synergistic antibiotics, the streptogramins. Thus, at least two pairs of structurally dissimilar compounds have been selected in the course of evolution to act synergistically by targeting neighboring sites in the ribosome. These results underscore the importance of the corresponding ribosomal sites for development of clinically relevant synergistic antibiotics and demonstrate the utility of structural analysis for providing new directions for drug discovery.

lankamycin | ribosomes | synergism | resistance | rRNA

Biochemical, genetic and functional evidence indicate that a great variety of antibiotics inhibit protein synthesis by binding to ribosomal functional regions. Crystallographic studies performed over the last decade revealed the exact binding sites of a variety of such drugs (see refs. 1 and 2 for review). Many natural antibiotics, as well as their clinically relevant semisynthetic derivatives, bind at the peptidyl transferase center (PTC) in the large ribosomal subunit (3–14). Most of these compounds inhibit cell growth by interfering with peptide bond formation (15). The second major antibiotic binding site in the large ribosomal subunit is located at the upper segment of the nascent peptide exit tunnel (NPET), adjacent to the PTC, and is used by macrolides and type B streptogramins (3, 7, 16–21). Binding to this site impedes progression of the nascent proteins toward the tunnel exit. Thus, compounds binding to the PTC and NPET inhibit successive steps in protein synthesis: formation of the nascent chains and their export from the ribosome.

Simultaneous inhibition of successive steps of a specific biochemical pathway often results in a synergistic action of the inhibitors (22). Nature has not ignored this opportunity when evolving ribosomal antibiotics. For example, streptogramin antibiotics, produced by several *Streptomyces* species, are secreted as a combination of two structurally distinct compounds that inhibit cell growth by acting upon the PTC and NPET (23, 24). Streptogramin A (S_A) compounds are cyclic poly-unsaturated macrolactones that bind in the PTC, whereas type B streptogramins (S_B) compounds are cyclic depsipeptides that bind in the NPET (6, 7, 25). Each of the individual streptogramin components is a fairly weak antibiotic on its own, but in combination they exhibit strong inhibitory action. The synergistic antibiotic effect of streptogramins is medically relevant—the semisynthetic

formulation Synercid composed of dalbapristin (the S_A derivative) and quinupristin (the S_B derivative) is widely used for treatment of complicated Gram-positive infections (26).

Lankacidin C (LC) and lankamycin (LM) are two inhibitory compounds produced by *Streptomyces rochei* 7434AN4 (27, 28). The structures of LC and LM are chemically distinct and rather different from those of streptogramins (Fig. 1). LC is a macrocyclic compound composed of a 17-membered carbocyclic ring, bridged by a 6-membered lactone. LM is a macrolide whose 14-member lactone ring is decorated with 4-acetyl-L-arcanose and D-chalchase sugars (29, 30) resembling erythromycin (ERY) (Fig. 1). LC, which is used in veterinary medicine, inhibits growth of Gram-positive bacteria by interfering with protein synthesis but has little effect on eukaryotic cell-free translation (31–34). LC and its derivatives also exhibit antitumor activity, although it is unclear whether this phenomenon is related to the drug's effect upon protein synthesis (35). Lankamycin exhibits a weak antibiotic activity against several Gram-positive bacteria and low toxicity in animal models (36, 37).

LC competition with chloramphenicol for binding to the ribosome reveals the large ribosomal subunit as a likely target of its action, in accord with its classification as a protein synthesis inhibitor (32, 38). Though little data is available about activity of LM, the similarity of its structure to that of ERY indicates that it may act as a typical macrolide. Furthermore, similar to ERY and other macrolides, desacetyl-LM was reported to be capable of activating expression of inducible macrolide-resistance genes (37). Coregulation of production of LC and LM (39, 40) suggests that these drugs have been evolutionary optimized to work together. Nevertheless, although LC and LM are coproduced by the *Streptomyces* strain, there has been no information about their sites of action, nor any evidence of functional interaction between these two antibiotic compounds.

Here, we investigated the sites of binding and the modes of action of LC and LM by crystallographic and biochemical analyses. We show that these two compounds bind at neighboring sites in the large ribosomal subunit, which partially overlap with the binding sites of two components of streptogramin antibiotics. We present evidence that LC can bind simultaneously with LM, and that the two drugs inhibit bacterial growth synergistically, suggesting that the structures of LC and LM have been optimized in the course of evolution to allow for their simultaneous cooperative action. Based on our structural results we also suggest means for enhancing their synergetic inhibitory effect. This study

Author contributions: A.Y., A.B. and A.S.M. designed research; T.A., I.M., I.W., E.Z., L.X., and D.K. performed research; C.D., A.B., I.M., and M.B. analyzed data; K.A. and H.K. contributed new reagents/analytic tools; and A.S.M. and A.Y. wrote the paper.

The authors declare no conflict of interest.

Freely available online through the PNAS open access option.

¹To whom correspondence should be addressed. E-mail: ada.yonath@weizmann.ac.il or shura@uic.edu.

This article contains supporting information online at www.pnas.org/cgi/content/full/0914100107/DCSupplemental.




Fig. 1. Chemical structures of antibiotics relevant to this study. Three pairs are shown, in each the compounds that bind to the PTC are in the Upper panel, and their mates that bind to the NPET are in the Lower panel immediately below them. Erythromycin is inserted for size and structure comparisons.

presents the cases in which crystallographic analysis provided functional insights that, in turn, stimulated advanced biochemical and genetic studies, which yielded further clinical implications.

Results

Lankacidin Binding Site. The 3.5 Å resolution (Table S1) difference electron density map calculated between the structure amplitudes of the large ribosomal subunits from *Deinococcus radiodurans* (D50S) in complex with LC (D50S-LC) and of the D50S native structure (41) allowed the unambiguous determination of the location (Fig. 2A) and conformation of LC in the PTC (Fig. 2B).

LC binding pocket is composed of nucleotides A2602, C2452, A2503, U2504, G2505, U2585, G2061, and U2506 (*E. coli* numbering throughout), and the bound LC is involved in an extensive

network of hydrophobic interactions with most of these nucleotides. Additionally, LC is positioned within hydrogen bond distance to N1 and N2 of G2061, the 2' ribose hydroxyls of A2503, and O5' of G2505 (Fig. 2B–D). It partially occupies the location of the amino acid attached to the 3' end of A site tRNA (Fig. 3A) and barely reaches the macrolide binding site (Fig. 3C). The repositioning of the rRNA residues that occurs as a consequence of LC binding creates a unique network of interactions between five reoriented nucleotides: U2506, G2505, G2581, C2610, and G2576. Within this network G2576 stacks upon G2505, C2610 stacks upon G2581, and the exocyclic amine of G2505 is at a hydrogen bonding distance from O2 of C2610. Also, the amino group of G2505 is within a hydrogen bond reach of O4 of U2506, which shifts toward the LC's 1,3 dicarbonyl system. These newly established contacts stabilize the placement of G2505 and U2506 in a conformation that favors binding of LC. Additionally, similar to pleuromutins that utilize a network of remote interactions, LC binding is influenced by the second-shell nucleotides, specifically G2576, A2062, C2530, U2531, C2507, U2584, G2581, C2610, and A2059. Thus, LC exploits the PTC's inherent flexibility for achieving high binding affinity (9, 10).

In its binding site, LC macrolactone ring fits in the shallow depression in the wall of the PTC A site, by forming van der Waals interactions with U2504, G2505 and U2506. The importance of these interactions to the drug binding is manifested by structure-activity studies that showed that hydrogenation of the macrocyclic ring alters its ring conformation and reduces the inhibitory activity of LC (43). The 2-methyl group at the lactone edge of the macrocyclic ring inserts in the opening of the hydrophobic crevice formed by the splayed out bases of A2451 and C2452. This cleft also hosts the aminoacyl moiety of A site-bound aminoacyl-tRNA and is involved in binding of other PTC-targeting antibiotics,




Fig. 2. Interaction of lankacidin with D50S PTC. (A) LC (cyan) binding site at the PTC of D50S. (B) Modeling of LC structure in the (Fo-Fc) difference electron density map, contoured at 1.0 σ . (C) Chemical structure diagram of interactions of LC with the PTC nucleotides. (D) A network of induced interactions (in gray) between five PTC nucleotide residues that stabilize LC binding. The wild-type conformations are shown in pink.




Fig. 3. Antibiotics in PTC and NPET of the ribosome. In all the panels, LC is shown in cyan and the amino acid-esterified 3' ends of A- and P- sites tRNAs are in blue and green, respectively (42). Ribosomal RNA backbone is colored in gray. (A) Superposition of LC and an S_A compound dalfopristin (metallic blue) in PTC (6). The dalfopristin's mate S_B component, quinupristin, in the NPET (6) is shown in gold. (B) Superposition of LC and several other PTC-targeting antibiotics in their D50S binding sites: A section through the volume occupied by LC is shown in transparent cyan; the drugs shown are: clindamycin (3) in magenta, tiamulin (5) in purple; retapamulin (9) in slate, chloramphenicol (3) in red, dalfopristin (6) in metallic blue and methymycin (14) in orange and quinupristin (6) in gold. (C) Left: The relative positions of LC and ERY (red, from ref. 3) in D50S; right: The marked short distance between LC and ERY indicates a potential steric clash, thus explaining the competition of the two drugs for binding to the ribosome.

including S_A antibiotic compounds such as dalfopristin and virginiamycin M (3, 13, 44). The overlap of the LC and chloramphenicol binding sites (Fig. 3B) provides the structural basis for their competition for binding to the ribosome (32).

Despite significant size differences (Fig. 1), the position of LC closely resembles those of dalfopristin (6) and virginiamycin M (4). However, substantial differences were observed in the interactions of these compounds with the ribosome. In the D50S-Synercid complex (6) dalfopristin ring extends significantly farther toward the P site (Fig. 3A). As LC binds in the PTC center, it causes the flexible base of A2602, which plays a major role in tRNA translocation (42, 45), to undergo a 45° rotation compared to its placement in native D50S or in Synercid-bound complex. U2585, the second flexible nucleotide that also seems to play a role in A-tRNA translocation, undergoes only a minor alteration in D50S-LC complex, while it is rotated by 180° in D50S-Synercid complex. This rotation seems to occur because of steric hindrance of the dalfopristin large macrocyclic ring and to the occupation of the S_B site by quinupristin, the S_B component of Synercid. Other important details distinguish binding of LC and dalfopristin. While both drugs are hydrogen-bonded to the G2061 exocyclic amine, an additional H bond links dalfopristin with G2061 2' hydroxyl (6). Both LC and Synercid induce a conformational change of C2610. However, in the D50S-LC complex C2610 stacks upon G2581 and is H-bonded to G2505, whereas in the D50S-Synercid complex it is flipped away because of steric hindrance caused by quinupristin. Additionally, while both LC and dalfopristin reorient the U2506 base, the shift of this base toward LC is unique.

Consistent with its binding to the functionally critical PTC, LC inhibited bacterial (*E. coli*) cell-free transcription-translation system, with a respectable IC_{50} of $1.5 \pm 0.1 \mu\text{M}$ (Fig. 4A).




Fig. 4. Effect of LC on (A) protein synthesis in the *E. coli* cell-free system and (B) peptide bond formation catalyzed by *S. aureus* 70S ribosomes (circles) or *D. radiodurans* large ribosomal subunits (squares). (C) Competition of LC with ^{14}C -ERY for binding to *D. radiodurans* 50S subunits. (D) Inhibition of cell-free translation (*E. coli*) by LM

Furthermore, confirming previous observation (32, 38), we found that the drug readily interfered with the peptide bond formation inhibiting the puromycin reaction catalyzed by either *Staphylococcus aureus* 70S ribosomes ($IC_{50} 0.32 \pm 0.02 \mu\text{M}$) or isolated large ribosomal subunits of *D. radiodurans* ($IC_{50} 10.0 \pm 6.0 \mu\text{M}$) (Fig. 4B). This result affirmed LC as an effective PTC inhibitor.

Lankacidin and Lankamycin Can Simultaneously Bind to the Ribosome.

S. rochei secretes two antibiotics, a 17-member ring macrocyclic LC and a 14-member ring macrolide LM. LM is structurally similar to ERY (Fig. 1) and thus we assumed that it is likely to bind to the ribosome at the site and orientation similar to ERY, namely at the NPET in immediate proximity to the PTC, the LC binding site. However, the comparison of the position of ERY in D50S (3) with the crystal structure of D50S-LC complex (Fig. 3C) revealed that the desosamine sugar of ERY approaches the macrocyclic ring of LC too close for simultaneous binding of both drugs. In agreement with this notion, competition experiments showed that LC displaced ^{14}C -ERY from D50S with IC_{50} of $355 \pm 26 \text{ nM}$ (Fig. 4C). These observations raised the question whether similar to ERY, LM will also compete with LC for ribosome binding. If so, why would an antibiotic-producing microorganism synthesize two competing drugs?

Since the lack of radiolabeled LC and LM precluded direct measurement of their binding to the ribosome, we applied an alternative technique to address this puzzle. We first verified that LM binds to the ribosome and inhibits protein synthesis. Indeed, in the *E. coli* cell-free system, LM inhibited translation (IC_{50} of $275 \pm 36 \mu\text{M}$) (Fig. 4D), arguing that the antibiotic does bind to the ribosome, albeit with only moderate affinity. RNA probing was then utilized to follow the binding of LC and LM to the ribosome. For the consistency of structural data, we carried out RNA probing experiments using *D. radiodurans* large ribosomal subunits. Binding of LC and LM was analyzed using chemical modifying reagents 1-cyclohexyl-3-(2-morpholinoethyl) carbodiimide metho-*p*-toluene sulfonate (CMCT) and dimethyl sulfate (DMS) (46).

In accord with crystallographic data, association of LC with D50S results in a strong protection of the PTC nucleotide residues U2506 and U2585 from CMCT modification (Fig. 5A). We also noted that upon LC binding, A2059 became partially protected from DMS, whereas modification of A2058 was increased (Fig. 5B). This effect correlated with the crystallographic

makes evolutionary sense: The same microorganism produces both S_A and S_B components, and their mutually enhanced action should be highly beneficial for the antibiotic producer. This notion initially did not seem to hold true for the macrocyclic LC and a macrolide LM. Our experiments showed that LC and ERY do not cooperate, but rather compete for binding to the *D. radiodurans* ribosome. Hindrance may result from a direct clash between ERY desosamine sugar and the LC macrocyclic ring (Fig. 3C) or by allosteric modulation of the binding site of one compound by binding of its counterpart. The altered DMS reactivity of A2058 and A2059, the nucleotides located in the heart of the macrolide binding site (Fig. 5A), upon the LC binding might be a reflection of such allostery. However, the competition between LC and ERY is not so surprising: These drugs are produced by different microorganisms and were not “designed” to work together. In contrast, LM is coproduced with LC. Both drugs appear to be coregulated, and thus similar to the streptogramins case, seem to be intended to work together (39, 40). In agreement with this hypothesis, our results show their simultaneous binding to the ribosome. The small structural differences between ERY and LM (Fig. 1) are likely to cause the variation in their binding properties. One of the important distinctions between LM and ERY is the nature of the C5-linked sugar residue (D-desosamine in ERY vs. D-chalose in LM). Even small modifications of desosamine in ERY can dramatically alter the antibiotic’s activity (52, 53). Replacement of 3’ dimethyl amine of ERY with a methoxy group in LM may facilitate accommodation of the C5-sugar residue in a narrow space left between the A2058/A2059 ridge and the bound LC molecule (see Fig. 3C). Similarly, minute modifications in the structure of the antibiotics or in their binding sites may have significant effects on their binding and properties (20, 37, 54, 55). LM on its own is a less potent protein synthesis inhibitor than ERY. However, LM reduced activity is compensated by its ability to act synergistically with LC. Thus, it appears that the LM synthetic pathway has been evolutionary optimized to generate a 14-member ring macrolide capable of simultaneous binding and synergistic action with LC. It is hardly a coincidence that two different combinations of synergistic protein synthesis inhibitors, the S_A and S_B components of streptogramins or LC and LM, utilize the same two adjacent sites in the large ribosomal subunit. These sites might be best suited within the ribosome for accommodating pairs of compounds that would be able to tightly bind and inhibit protein synthesis in a synergistic fashion. Previously, significant resources went into development of streptogramins into a clinical drug. This effort resulted in a useful and successful streptogramin antibiotic, Synercid. Yet, to the best of our knowledge, no focused attempt was dedicated to optimizing the combination of LC/LM or, for that matter, LC with any other macrolide. Our studies demonstrate the validity of LC/LM synergism and provide a structural basis for chemical modifications of either of the two components,

which could lead to the improvement of the inhibitory action of the LC/LM pair and its clinical relevance. Notably, the S_A compounds (for example quinupristin or virginiamycin S) are significantly larger than LC (Figs. 1 and 3A) and therefore have more chemical entities facilitating their binding to the ribosome pocket and forming a stable network of interactions. It is likely, therefore, that decorating LC with additional groups capable of forming new interaction with rRNA in its binding site may increase its affinity. Modulating the properties of the LM sugar residues may further add to the potency of the LC/LM pair.

Conclusions

We showed that two antibiotics, LC and LM, produced by *S. rochei* are protein synthesis inhibitors that act upon neighboring sites in the large ribosomal subunit and that their simultaneous action synergistically inhibits growth of sensitive bacteria. Our structural and biochemical data imply that optimization of this drug pair leading to high affinity concurrent binding to the ribosome may be reached by minor chemical alterations. Furthermore, our results suggest that certain combinations of PTC inhibitors with the NPET-bound compounds in their natural or chemically modified versions might exhibit synergy. Exploring such drug combinations by *co*-optimizing their structure or by linking them together into a single molecule may pave the way for the development of advanced antibiotics targeting the ribosome.

Materials and Methods

Crystals of D50S, grown as in ref. 41, were soaked in a solution containing lankacidin. Crystallographic data were collected with highly collimated synchrotron x-ray beam and processed with HKL2000 (56) and CCP4 (57) using the available crystal structure of lankacidin C (29). After map tracing and refinement by COOT (58) and CNS (59, 60) ribosome-antibiotic interactions were identified by LigPlot (61) and LPC (62), and images were generated by PyMol (63). Coordinates were deposited in the protein data bank (PDB) with accession code 3JQ4.

Antibiotic binding and inhibition of cell-free translation were determined as described in ref. 64. Inhibition of the peptidyl transferase reaction by LC was performed and analyzed as described in refs. 65 and 66. The data were analyzed using Prism 4 (GraphPad Software). RNA probing was carried out as described in ref. 16 and 46 using D50S. Additional details can be found in *SI Text*.

ACKNOWLEDGMENTS. We thank the ribosome group at the Weizmann Institute for participating in the experiments reported here and Dr. Llano-Sotelo (University of Illinois at Chicago) for helping with the analysis of the inhibitory and competition data. We thank Dr. Weisblum (University of Wisconsin) for providing initial samples of lankamycin and Pfizer, Inc. for lankacidin. Crystallographic data were collected at station 19ID at the Advanced Photon Source (Argonne National Laboratory) and ID23-2 at the European Synchrotron Radiation Facility, and we thank the staff of both facilities for excellent assistance. This work was supported by National Institutes of Health grants GM34360 (to A.Y.) and U19 AI56575 (to A.S.M.) and by the Kimmelman Center for Macromolecular Assemblies. CD is supported by the Adams Fellowship Program of the Israel Academy of Sciences and Humanities. A.Y. holds the Martin and Helen Kimmel Professorial Chair.

- Poehlsaard J, Douthwaite S (2005) The bacterial ribosome as a target for antibiotics. *Nat Rev Microbiol*, 3(11):870–881.
- Böttger EC (2006) The ribosome as a drug target. *Trends Biotechnol*, 24(4):145–147.
- Schluenzen F, et al. (2001) Structural basis for the interaction of antibiotics with the peptidyl transferase center in eubacteria. *Nature*, 413(6858):814–821.
- Hansen JL, et al. (2003) Structures of five antibiotics bound at the peptidyl transferase center of the large ribosomal subunit. *J Mol Biol*, 330(5):1061–1075.
- Schluenzen F, et al. (2004) Inhibition of peptide bond formation by pleuromutilins: The structure of the 50S ribosomal subunit from *Deinococcus radiodurans* in complex with tiamulin. *Mol Microbiol*, 54(5):1287–1294.
- Harms J, et al. (2004) Inhibition of peptide bond formation by the ribosome induced by the synergistic action of the streptogramins dalbopristin and quinupristin. *BMC Biol*, 2(1):4:1–10.
- Tu D, et al. (2005) Structures of MLSBK antibiotics bound to mutated large ribosomal subunits provide a structural explanation for resistance. *Cell*, 121:257–270.
- Leach KL, et al. (2007) The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria. *Mol Cell*, 26(3):393–402.
- Davidovich C, et al. (2007) Induced-fit tightens pleuromutilins binding to ribosomes and remote interactions enable their selectivity. *Proc Natl Acad Sci USA*, 104(11):4291–4296.
- Davidovich C, et al. (2008) Structural basis for cross-resistance to ribosomal PTC antibiotics. *Proc Natl Acad Sci USA*, 105(52):20665–20670.
- Ippolito JA, et al. (2008) Crystal structure of the oxazolidinone antibiotic linezolid bound to the 50S ribosomal subunit. *J Med Chem*, 51(12):3353–3356.
- Wilson DN, et al. (2008) The oxazolidinone antibiotics perturb the ribosomal peptidyl-transferase center and effect tRNA positioning. *Proc Natl Acad Sci USA*, 105(26):13339–13344.
- Gurel G, et al. (2009) U2504 determines the species specificity of the A-site cleft antibiotics the structures of tiamulin, homoharringtonine, and bruceantin bound to the ribosome. *J Mol Biol*, 389(1):146–156.
- Auerbach T, et al. (2009) Structural basis for the antibacterial activity of the 12-membered-ring mono-sugar macrolide methymycin. *Biotechnol*, 84:24–35.
- Polacek N, Mankin AS (2005) The ribosomal peptidyl transferase center: Structure, function, evolution, inhibition. *Crit Rev Biochem Mol Biol*, 40(5):285–311.
- Moazed D, Noller HF (1987) Chloramphenicol, erythromycin, carbomycin and vernalmycin B protect overlapping sites in the peptidyl transferase region of 23S ribosomal RNA. *Biochimie*, 69:879–884.
- Xiong L, et al. (1999) A ketolide resistance mutation in domain II of 23S rRNA reveals the proximity of hairpin 35 to the peptidyl transferase center. *Mol Microbiol*, 31(2):633–639.

18. Schluenzen F, et al. (2003) Structural basis for the antibiotic activity of ketolides and azalides. *Structure*, 11(3):329–338.
19. Berisio R, et al. (2003) Structural insight into the antibiotic action of telithromycin against resistant mutants. *J Bacteriol*, 185(14):4276–4279.
20. Berisio R, et al. (2003) Structural insight into the role of the ribosomal tunnel in cellular regulation. *Nat Struct Biol*, 10(5):366–370.
21. Liu M, Douthwaite S (2002) Resistance to the macrolide antibiotic tylosin is conferred by single methylations at 23S rRNA nucleotides G748 and A2058 acting in synergy. *Proc Natl Acad Sci USA*, 99(23):14658–14663.
22. Acar JF (2000) Antibiotic synergy and antagonism. *Med Clin N Am*, 84(6):1391–1406.
23. Vazquez D () Mechanism of action of antimicrobial and antitumor agents. In *Antibiotics III*, ed Corcoran JW(1975) (Springer-Verlag), pp 521–534.
24. Cocito C, et al. (1997) Inhibition of protein synthesis by streptogramins and related antibiotics. *J Antimicrob Chemother*, 39(Suppl A):7–13.
25. Canu A, et al. (2002) Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycin in *Streptococcus pneumoniae*. *Antimicrob Agents Chemother*, 46(1):125–131.
26. Delgado G, Jr, et al. (2000) Quinupristin-dalfopristin: An overview. *Pharmacotherapy*, 20(12):1469–1485.
27. Gaumann E, et al. (1960) Stoffwechselprodukte von Actinomyceten. 21. Mitteilung. Lankamycin und Lankacidin. *Helv Chim Acta*, 43(2):601–606.
28. Kinashi H, et al. (1994) Isolation and characterization of linear plasmids from lankacidin-producing *Streptomyces* species. *J Antibiot*, 47(12):1447–1455.
29. Uramoto M, et al. (1969) The structures of Bundlin A (lankacidin) and Bundlin B. *Tetrahedron Lett*, 27:2249–2254.
30. Harada S, et al. (1969) Isolation and structures of T-2636 antibiotics. *Tetrahedron Lett*, 27:2239–2244.
31. Harada S, et al. (1973) Studies on lankacidin-group (T-2636) antibiotics. VII. Structure-activity relationships of lankacidin-group antibiotics. *J Antibiot*, 26(11):647–657.
32. Retsema JA, et al. (1995) *New Macrolides, Azalides, and Streptogramins in Clinical Practice*, ed Neu HC (Marcel), pp 191–195.
33. McFarland JW, et al. (1984) Side chain modifications in lankacidin group antibiotics. *Antimicrob Agents Chemother*, 25(2):226–233.
34. Mochizuki S, et al. (2003) The large linear plasmid pSLA2-L of *Streptomyces rochei* has an unusually condensed gene organization for secondary metabolism. *Mol Microbiol*, 48(6):1501–1510.
35. Oostu K, et al. (1975) Antitumor and immunosuppressive activities of lankacidin-group antibiotics: Structure-activity relationships. *Cancer Chemother Rep*, 59(5):919–928.
36. Martin JR, et al. (1976) 3'-de-o-methyl-2', 3'-anhydro-lankamycin, a new macrolide antibiotic from *Streptomyces violaceoniger*. *Helv Chim Acta*, 59(5):1886–1894.
37. Omura S, et al. (1969) Studies on the antibiotics from *Streptomyces spinichromogenes* var. *kujimyceticus*. II. Isolation and characterization of kujimycins A and B. *J Antibiot*, 22(10):500–505.
38. Retsema J, Fu W (2001) Macrolides: Structures and microbial targets. *Int J Antimicrob Ag*, 18(Suppl 1):3–10.
39. Arakawa K, et al. (2007) gamma-Butyrolactone autoregulator-receptor system involved in lankacidin and lankamycin production and morphological differentiation in *Streptomyces rochei*. *Microbiology*, 153(Pt 6):1817–1827.
40. Yamamoto S, et al. (2008) Gamma-butyrolactone-dependent expression of the *Streptomyces* antibiotic regulatory protein gene *srrY* plays a central role in the regulatory cascade leading to lankacidin and lankamycin production in *Streptomyces rochei*. *J Bacteriol*, 190(4):1308–1316.
41. Harms J, et al. (2001) High resolution structure of the large ribosomal subunit from a mesophilic eubacterium. *Cell*, 107(5):679–688.
42. Kamiya K, et al. (1969) x-ray analysis of an antibiotic, T-2636 A (Bundlin B). *Tetrahedron Lett*, 27:2245–2248.
43. Hansen JL, et al. (2002) The structures of four macrolide antibiotics bound to the large ribosomal subunit. *Mol Cell*, 10(1):117–128.
44. Bashan A, et al. (2003) Structural basis of the ribosomal machinery for peptide bond formation, translocation, and nascent chain progression. *Mol Cell*, 11:91–102.
45. Agmon I, et al. (2004) Ribosomal crystallography: a flexible nucleotide anchoring tRNA translocation, facilitates peptide-bond formation, chirality discrimination and antibiotics synergism. *FEBS Lett*, 567(1):20–26.
46. Merryman C, Noller HF (1998) Footprinting and modification-interference analysis of binding sites on RNA. *RNA:Protein Interactions*, ed Smith CWJ (Oxford Univ Press, UK), pp 237–253.
47. Hardman JG, Limbird LE, Molinoff PB, Ruddon RW (1996) Goodman & Gilman's The Pharmacological Basis of Therapeutics. (McGraw-Hill), pp 1046–1049.
48. Moazed D, Noller HF (1989) Interaction of tRNA with 23S rRNA in the ribosomal A, P, and E sites. *Cell*, 57(4):585–597.
49. Zarivach R, et al. (2004) Functional aspects of ribosomal architecture: Symmetry, chirality and regulation. *J Phys Org Chem*, 17:901–912.
50. Schmeing TM, et al. (2005) An induced-fit mechanism to promote peptide bond formation and exclude hydrolysis of peptidyl-tRNA. *Nature*, 438(7067):520–524.
51. Porse BT, Garrett RA (1999) Sites of interaction of streptogramin A and B antibiotics in the peptidyl transferase loop of 23 S rRNA and the synergism of their inhibitory mechanisms. *J Mol Biol*, 286(2):375–387.
52. Wu YJ, Su WG (2001) Recent developments on ketolides and macrolides. *Curr Med Chem*, 8(14):1727–1758.
53. Yonath A (2005) Antibiotics targeting ribosomes: Resistance, selectivity, synergism, and cellular regulation. *Annu Rev Biochem*, 74:649–679.
54. Vazquez-Laslop N, et al. (2008) Molecular mechanism of drug-dependent ribosome stalling. *Mol Cell*, 30(2):190–202.
55. Pfister P, et al. (2005) 23S rRNA base pair 2057-2611 determines ketolide susceptibility and fitness cost of the macrolide resistance mutation 2058A -- > G. *Proc Natl Acad Sci USA*, 102(14):5180–5185.
56. Otwinowski Z, Minor W (1997) Processing of x-ray diffraction data collected in oscillation mode, methods in enzymology. *Macromolecular Crystallography*, ed Carter JCW pp:307–326.
57. CCP4 (1994) Collaborative Computational Project, Number 4, The CCP4 Suite: Programs for Protein Crystallography. *Acta Crystallogr D*, pp:760–763.
58. Emsley P, Cowtan K (2004) Coot: Model-building tools for molecular graphics. *Acta Crystallogr D*, 60(Pt 12 Pt 1):2126–2132.
59. Brunger AT, et al. (1998) Crystallography & NMR system: A new software suite for macromolecular structure determination. *Acta Crystallogr D*, 54(Pt 5):905–921.
60. Brunger AT (2007) The crystallography and NMR system. *Nat Protoc*, 2(11):2728–2733.
61. Wallace AC, et al. (1995) LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. *Protein Eng*, 8(2):127–134.
62. Sobolev V, et al. (1999) Automated analysis of interatomic contacts in proteins. *Bioinformatics*, 15(4):327–332.
63. DeLano WL (2002) The PyMOL Molecular Graphics System. (DeLano Scientific, Palo Alto, CA).
64. Xiong L, et al. (2005) Binding Site of the Bridged Macrolides in the *Escherichia coli* Ribosome. *Antimicrob Agents Chemother*, 49(1):281–288.
65. Maguire BA, et al. (2005) A protein component at the heart of an RNA machine: the importance of protein L27 for the function of the bacterial ribosome. *Mol Cell*, 20(3):427–436.
66. Bartetzko A, Nierhaus KH (1988) Mg²⁺ /NH₄⁺ /polyamine system for polyuridine-dependent polyphenylalanine synthesis with near in vivo characteristics. *Methods Enzymol*, 164:650–658.